Thinking that a delay in a companies previously cited ' on track' process will entice big pharma to try and look at purchasing it more cheaply is A+ grade copium.
Acquisition etc simply don't work like that.
To be picked up, you need to produce results.
usually phase 3 results.
To produce results, you need product.
PAT-DX1 is delayed for a phase 1 trial due to this manufacturing delay.
Yes, I'm aware that DX3 is what many consider to be the big ticket item, but trying to spin a manufacturing delay as a positive for any potential bigger company sniffing around is just foolish.
Ann: Updated guidance for PAT-DX1 phase 1 clinical study, page-43
-
- There are more pages in this discussion • 83 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.37M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 27 | 5101591 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 1558945 | 5 |
View Market Depth
| Last trade - 09.58am 17/07/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable